AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions.
AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions.